SPRO – Spero Therapeutics, Inc.
Spero Therapeutics, Inc.SPRO
$0.582Name : Spero Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $32,534,150.00
EPSttm : -1.27
Spero Therapeutics, Inc.
$0.582
6.73%$0.042Float Short %
1.16
Margin Of Safety %
Put/Call OI Ratio
0.03
EPS Next Q Diff
-0.19
EPS Last/This Y
-1.05
EPS This/Next Y
0.34
Price
0.63
Target Price
5
Analyst Recom
2.33
Performance Q
-46.11
Relative Volume
1.57
Beta
0.26
Ticker: SPRO
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-05 | SPRO | 0.7702 | 0.02 | 0.00 | 1403 |
| 2025-03-06 | SPRO | 0.788 | 0.02 | 0.00 | 1403 |
| 2025-03-07 | SPRO | 0.7711 | 0.02 | 0.00 | 1403 |
| 2025-03-10 | SPRO | 0.7599 | 0.02 | 0.00 | 1403 |
| 2025-03-11 | SPRO | 0.74 | 0.02 | 0.00 | 1407 |
| 2025-03-12 | SPRO | 0.76 | 0.02 | 0.00 | 1407 |
| 2025-03-13 | SPRO | 0.7894 | 0.02 | 0.00 | 1407 |
| 2025-03-14 | SPRO | 0.7823 | 0.02 | 0.00 | 1407 |
| 2025-03-17 | SPRO | 0.7701 | 0.02 | 0.00 | 1407 |
| 2025-03-18 | SPRO | 0.7648 | 0.02 | 0.00 | 1411 |
| 2025-03-19 | SPRO | 0.7647 | 0.02 | 0.00 | 1411 |
| 2025-03-20 | SPRO | 0.7682 | 0.02 | 0.00 | 1411 |
| 2025-03-21 | SPRO | 0.82 | 0.02 | 0.00 | 1413 |
| 2025-03-24 | SPRO | 0.8109 | 0.02 | 0.00 | 1413 |
| 2025-03-25 | SPRO | 0.845 | 0.03 | 0.00 | 1262 |
| 2025-03-26 | SPRO | 0.89 | 0.03 | 0.00 | 1273 |
| 2025-03-27 | SPRO | 0.8601 | 0.03 | 0.00 | 1276 |
| 2025-03-28 | SPRO | 0.7725 | 0.03 | 0.00 | 1276 |
| 2025-03-31 | SPRO | 0.72 | 0.03 | 0.00 | 1282 |
| 2025-04-01 | SPRO | 0.6841 | 0.03 | 0.00 | 1282 |
| 2025-04-02 | SPRO | 0.7149 | 0.03 | 0.00 | 1302 |
| 2025-04-03 | SPRO | 0.6351 | 0.03 | 10.00 | 1302 |
| 2025-04-04 | SPRO | 0.63 | 0.03 | 999.99 | 1312 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-05 | SPRO | 0.78 | -132.3 | - | -1.29 |
| 2025-03-06 | SPRO | 0.78 | -132.3 | - | -1.29 |
| 2025-03-07 | SPRO | 0.77 | -132.3 | - | -1.29 |
| 2025-03-10 | SPRO | 0.77 | -132.3 | - | -1.29 |
| 2025-03-11 | SPRO | 0.74 | -132.3 | - | -1.29 |
| 2025-03-12 | SPRO | 0.75 | -132.3 | - | -1.29 |
| 2025-03-13 | SPRO | 0.78 | -132.3 | - | -1.29 |
| 2025-03-14 | SPRO | 0.78 | -132.3 | - | -1.29 |
| 2025-03-17 | SPRO | 0.77 | -132.3 | - | -1.29 |
| 2025-03-18 | SPRO | 0.75 | -132.3 | - | -1.29 |
| 2025-03-19 | SPRO | 0.76 | -132.3 | - | -1.29 |
| 2025-03-20 | SPRO | 0.78 | -132.3 | - | -1.29 |
| 2025-03-21 | SPRO | 0.80 | -132.3 | - | -1.29 |
| 2025-03-24 | SPRO | 0.82 | -132.3 | - | -1.29 |
| 2025-03-25 | SPRO | 0.90 | -132.3 | - | -1.29 |
| 2025-03-26 | SPRO | 0.89 | -132.3 | - | -1.29 |
| 2025-03-27 | SPRO | 0.88 | -132.3 | - | -1.29 |
| 2025-03-28 | SPRO | 0.77 | -132.3 | - | -1.29 |
| 2025-03-31 | SPRO | 0.72 | -10.4 | - | -0.79 |
| 2025-04-01 | SPRO | 0.69 | -10.4 | - | -0.79 |
| 2025-04-02 | SPRO | 0.71 | -10.4 | - | -0.79 |
| 2025-04-03 | SPRO | 0.62 | -10.4 | - | -0.79 |
| 2025-04-04 | SPRO | 0.63 | -129.2 | - | -2.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-05 | SPRO | -1.88 | 11.84 | 1.17 |
| 2025-03-06 | SPRO | -1.88 | 11.84 | 1.17 |
| 2025-03-07 | SPRO | -1.88 | 11.84 | 1.17 |
| 2025-03-10 | SPRO | -1.88 | 11.92 | 1.17 |
| 2025-03-11 | SPRO | -1.88 | 11.92 | 1.17 |
| 2025-03-12 | SPRO | -1.88 | 11.92 | 1.16 |
| 2025-03-13 | SPRO | -1.88 | 11.92 | 1.16 |
| 2025-03-14 | SPRO | -1.88 | 11.92 | 1.16 |
| 2025-03-17 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-18 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-19 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-20 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-21 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-24 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-25 | SPRO | -1.88 | 9.28 | 1.16 |
| 2025-03-26 | SPRO | -1.88 | 9.28 | 1.19 |
| 2025-03-27 | SPRO | -1.88 | 9.28 | 1.19 |
| 2025-03-28 | SPRO | -1.88 | 9.28 | 1.19 |
| 2025-03-31 | SPRO | -1.88 | 9.03 | 1.19 |
| 2025-04-01 | SPRO | -1.88 | 9.03 | 1.19 |
| 2025-04-02 | SPRO | -1.88 | 9.03 | 1.19 |
| 2025-04-03 | SPRO | -1.88 | 9.03 | 1.19 |
| 2025-04-04 | SPRO | -1.83 | 9.03 | 1.16 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.38
Avg. EPS Est. Current Quarter
-0.27
Avg. EPS Est. Next Quarter
-0.57
Insider Transactions
-1.83
Institutional Transactions
9.03
Beta
0.26
Average Sales Estimate Current Quarter
11
Average Sales Estimate Next Quarter
Fair Value
Quality Score
18
Growth Score
36
Sentiment Score
3
Actual DrawDown %
97.3
Max Drawdown 5-Year %
-97.1
Target Price
5
P/E
Forward P/E
PEG
P/S
1.19
P/B
0.69
P/Free Cash Flow
EPS
-1.27
Average EPS Est. Cur. Y
-2.32
EPS Next Y. (Est.)
-1.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-250.28
Relative Volume
1.57
Return on Equity vs Sector %
-168.5
Return on Equity vs Industry %
-155.5
EPS 1 7Days Diff
-1.5
EPS 1 30Days Diff
-1.53
EBIT Estimation
Spero Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 32
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
stock quote shares SPRO – Spero Therapeutics, Inc. Stock Price stock today
news today SPRO – Spero Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SPRO – Spero Therapeutics, Inc. yahoo finance google finance
stock history SPRO – Spero Therapeutics, Inc. invest stock market
stock prices SPRO premarket after hours
ticker SPRO fair value insiders trading